| |
| |
|
| Insider
Information: |
Turtle Cameron |
| Relationship: |
|
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
759,475 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$800,697 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
759,475 |
|
|
| Total
Value |
$800,697 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eidos Therapeutics, Inc. |
EIDX |
Chief Business Officer |
2021-01-26 |
0 |
2018-11-30 |
0 |
Premium* |
|
|
Bridgebio Pharma, Inc. |
BBIO |
See Remarks |
2020-12-28 |
12,568 |
2019-07-01 |
0 |
Premium* |
|
|
Aeglea Biotherapeutics, Inc. |
AGLE |
|
2024-02-15 |
746,907 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
56 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2018-11-30 |
4 |
A |
$12.01 |
$12,983 |
D/D |
1,081 |
108,386 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2019-05-31 |
4 |
A |
$12.01 |
$21,246 |
D/D |
1,769 |
110,155 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-05-31 |
4 |
A |
$41.57 |
$15,632 |
D/D |
376 |
75,531 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,745 |
12,568 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Chief Executive Officer |
• • – |
2023-11-24 |
4 |
A |
$0.00 |
$0 |
D/D |
723,440 |
746,507 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Chief Executive Officer |
• • – |
2024-02-15 |
4 |
A |
$9.82 |
$3,928 |
D/D |
400 |
746,907 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-01-08 |
4 |
AS |
$34.17 |
$440,211 |
D/D |
(12,807) |
9,823 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-02-03 |
4 |
AS |
$53.32 |
$670,640 |
D/D |
(12,500) |
80,155 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-02-11 |
4 |
AS |
$37.28 |
$74,564 |
D/D |
(2,000) |
9,823 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-04-08 |
4 |
AS |
$27.04 |
$216,358 |
D/D |
(8,000) |
9,823 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-04-27 |
4 |
AS |
$32.01 |
$64,028 |
D/D |
(2,000) |
9,823 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-05-01 |
4 |
AS |
$40.52 |
$408,433 |
D/D |
(10,000) |
75,155 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-05-26 |
4 |
AS |
$47.00 |
$117,500 |
D/D |
(2,500) |
75,155 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-08-03 |
4 |
AS |
$39.05 |
$399,450 |
D/D |
(10,000) |
70,531 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-09-10 |
4 |
AS |
$47.00 |
$117,500 |
D/D |
(2,500) |
70,531 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-09-11 |
4 |
AS |
$35.02 |
$70,047 |
D/D |
(2,000) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-09-15 |
4 |
AS |
$37.06 |
$92,652 |
D/D |
(2,500) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-09-18 |
4 |
AS |
$42.01 |
$105,024 |
D/D |
(2,500) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-09-30 |
4 |
AS |
$37.59 |
$546,458 |
D/D |
(14,500) |
12,568 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2020-11-02 |
4 |
AS |
$70.44 |
$883,954 |
D/D |
(12,500) |
65,531 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-11-05 |
4 |
AS |
$42.05 |
$105,125 |
D/D |
(2,500) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-11-24 |
4 |
AS |
$47.00 |
$200,137 |
D/D |
(4,258) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-11-25 |
4 |
AS |
$47.23 |
$35,044 |
D/D |
(742) |
12,568 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• – – |
2020-12-28 |
4 |
AS |
$69.34 |
$1,357,184 |
D/D |
(19,500) |
12,568 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Business Officer |
• – – |
2021-01-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(50,699) |
0 |
0 |
- |
|
56 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
